Details:
Through the agreement, Duke-NUS will propose drug targets to IPG, which will, in turn, identify and develop lead compounds with the goal of licensing clinic-ready candidates to pharmaceutical companies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Duke-NUS Medical School
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 07, 2023
Details:
The financing will be used for the development of Alpha Fusion's pipeline including Astatine-211, an element belonging to halogens and has the property of emitting alpha particle.
Lead Product(s): Astatine-211
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Sumitomo Heavy Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 07, 2023
Details:
As part of the license agreement, Exelixis will have the right to use the AJICAP technology to support its aim of advancing multiple Antibody-drug Conjugates with the potential for higher efficacy and lower toxicity than currently available options.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2023
Details:
Extension of the research collaboration term to allow for additional peptide-RI conjugate discovery and development programs. RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan to the joint peptide-RI programs.
Lead Product(s): Peptide-radioisotope Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Peptide
Partner/Sponsor/Collaborator: RayzeBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 09, 2022
Details:
Taiho Pharmaceutical announces that it and Astex Pharmaceuticals, both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 13, 2021
Details:
Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: TransThera Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
Details:
Under the terms of the agreement, Recursion obtains exclusive worldwide rights to develop and commercialize TAK-733.
Lead Product(s): Tak-733
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Recursion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2020